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SYSTEMATIC REVIEW OF MEDICAL 
EVIDENCE 
John P.A. Ioannidis, M.D. & Joseph Lau, M.D.* 
I.  THE NEED FOR SYSTEMATIC REVIEWS OF MEDICAL EVIDENCE 
Medical questions that arise in everyday clinical practice are 
often complex. The fascinating advances of the basic biomedical 
sciences of the last two decades, such as the mapping of the human 
genome, have created a widespread notion in the general public 
that medical knowledge is highly advanced, well founded, 
scientifically documented, and exact. Despite considerable 
progress, however, the clinical practice aspect of the medical 
science has not reached the same level of exactness as the physical 
sciences or even the basic biological sciences. The complexity of 
the human organism and the unpredictable nature of interactions 
between specific interventions and specific patients are difficult to 
reduce to the simplicity of physical laws. Knowledge about 
molecular and cellular mechanisms is enlightening, and animal 
data are very useful for medical progress, but it cannot be taken for 
granted that they will be readily translated to medical practice, let 
alone to the care of individual patients. First, basic knowledge 
from biological and animal systems must be verified in humans, 
and evidence must be corroborated from the application of various 
medical interventions in patients. Biological concepts must be 
tested in large numbers of human subjects to reduce the level of 
statistical uncertainty. Even when this is done, highly promising 
findings of basic biological research often do not turn out to hold 
                                                          
 * John P.A. Ioannidis, M.D. is Adjunct Professor of Medicine, Tufts 
University. Joseph Lau, M.D. is Professor of Medicine, Institute for Clinical 
Research and Health Policy Studies, Tufts-New England Medical Center. 
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true in routine clinical settings.1 
An outsider may expect decisions about the best medical action 
in a specific setting, the alternatives, and whether some actions are 
clearly inadequate or unacceptable, to be uncomplicated. Yet, 
medical decisions often involve a large number of complex clinical 
questions. Typically several decisions need to be made 
concurrently or sequentially. This is most clear in the case of 
hospitalized patients who have several medical problems that may 
affect each other. These patients may already be receiving many 
medications, and while each one of the medications may have been 
tested alone in clinical studies, there may be limited knowledge on 
their interactions. In addition, the clinical course of hospitalized 
patients may be very fragile, and rapid changes in their conditions 
may occur. The available background information for making 
rapid decisions may vary, and it is not uncommon for even 
experienced physicians to miss large parts of the diagnostic puzzle 
or even the main diagnosis itself. For patients with highly complex 
interrelated problems, there may be little instructive precedent in 
the medical literature on how to handle similar cases with the same 
combination of problems. For example, for a patient with 
hypertension (increased blood pressure), there may be extensive 
data available on similar cases, since one in five Americans has 
high blood pressure.2 On the other hand, prior knowledge may be 
more limited and more difficult to apply when someone also has 
heart disease, diabetes mellitus, high cholesterol, osteoporosis, 
liver dysfunction, kidney impairment, and is already taking several 
medications. 
Even for uncomplicated situations, medical decision-making 
still can be quite challenging. For a healthy young woman who 
                                                          
1 See Despina G. Contopoulos-Ioannidis et. al., Translation of Highly 
Promising Basic Science Research into Clinical Applications, 114 AM. J. MED. 
477 (2003) (reporting that of 101 findings published in major basic science 
journals from 1977 through 1982 where explicit promises were made for clinical 
applications, only 5 of them had resulted in some licensed clinical use twenty 
years later and only one of them had a considerable clinical impact). 
2 See American Heart Association, High Blood Pressure Statistics, at 
http://www.americanheart.org/presenter.jhtml?identifier=4621 (last visited 
March 2, 2004). 
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comes to a physician for a routine check-up, there are many 
decisions to make. One of the many decisions may be whether to 
offer mammography as a screen test for breast cancer. Screening 
mammography has been recommended by several professional 
organizations and government agencies and is widely deemed as 
an effective means to reduce breast cancer mortality; yet, this 
apparently straightforward recommendation is controversial, and 
the evidence supporting this recommendation has been 
challenged.3 As all medical tests suffer from unavoidable errors, 
finding an abnormality on a mammogram does not necessarily 
mean the woman has breast cancer. It is possible that the 
abnormality may be a case of “false positive” results. False 
positive results are inherent uncertainties in the ability of a test to 
differentiate disease from non-disease conditions; even the best 
tests are susceptible to false positive results, even when performed 
carefully with state-of-the-art equipment. A false positive test can 
lead down a path of undesirable outcomes as a consequence of 
further testing and medical management. For example, a woman 
who has a false positive mammogram suggesting abnormalities is a 
candidate for a breast biopsy. While the risk of serious 
complications resulting from a breast biopsy is low, it still carries 
small risks of bleeding and infection, and it also creates anxiety in 
the patient. For other potentially more dangerous tests like liver 
biopsy, serious bleeding may lead to hospitalization. Hospital 
admission may lead to other complications, such as acquiring an 
infection while in the hospital. In all, every action in medicine has 
to be carefully balanced for its potential benefits and risks,4 and it 
is often difficult to take into account all the possible interactions 
and developments in patients. 
The complexity and uncertainty in medical decision-making 
has shown that it is very important to utilize the best available 
evidence in each case and to scrutinize the quality of the evidence 
                                                          
3 See, e.g., Peter C. Gotzsche & Ole Olsen, Is Screening for Breast Cancer 
with Mammography Justifiable?, 255 LANCET 129 (2000). 
4 For a discussion of approaches towards balancing risks against benefits, 
see Paul P. Glasziou & Les Irwig, An Evidence Based Approach to 
Individualising Treatment, 311 BRIT. MED. J. 1356 (1995). 
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accumulated from past medical research. The questions are, where 
should this evidence come from, and how should it be appraised 
and synthesized to arrive at a most meaningful and seasoned 
decision? 
II.  OVERVIEW OF THE HIERARCHY OF MEDICAL EVIDENCE 
A.  Expert Opinion 
Medical practice and policy-making often relied on expert 
opinions. Expert opinions may be offered as patient care 
consultations, informal discussions among colleagues, lectures, or 
in written forms as book chapters, review articles, or editorials. In 
the last few decades, there has been an increasing recognition that 
relying on expert opinion to make medical decision has significant 
shortcomings. Analyses of medical review articles have shown that 
coverage of the potentially relevant data by the authors is often 
sketchy, anecdotal, and highly subjective or even biased.5 The 
proposed recommendations may not represent the findings of the 
actual data from medical studies, and sometimes the 
recommendations may be in favor of totally ineffective therapies, 
or against therapies that have been shown to be beneficial.6 
The unbalanced reviews offered by experts should not be 
surprising. In the current era of the information revolution, the 
amount of medical information that is being generated is 
staggering. Over a million biomedical articles are published in 
international journals every year. Even an expert in a highly 
                                                          
5 The first major assessment of the deficiencies of the traditional review 
article in the medical literature was published in 1987. See Cynthia D. Mulrow, 
The Medical Review Article: State of the Science, 106 ANNALS INTERNAL MED. 
485 (1987). 
6 In 1992, it was shown that the best written documents based on expert 
opinion often failed to follow what the true data suggested in the treatment of 
acute myocardial infarction, and sometimes they even contradicted the data. See 
Eliott M. Antman et. al., A Comparison of Results of Meta-analyses of 
Randomized Control Trials and Recommendations of Clinical Experts. 
Treatments for Myocardial Infarction, 268 J. AM. MED. ASS’N 240 (1992). 
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specialized field would have to read many thousands of articles a 
year to be certain that she is not missing essential information. The 
variable quality of this information further adds to the problem, 
since one needs to have considerable training in research 
methodology and to spend a lot of time evaluating the strengths 
and limitations of each study. Experts who are influential often are 
excellent in their specialty, but they may lack formal training in 
research methodologies and in critically reviewing the literature. In 
addition, subjectivity is unavoidable. Finally, it is probably quite 
common for experts to have some conflicts of interest, financial or 
otherwise, or topics in which they have invested their careers or 
reputations.7 The relative contribution of these reasons towards the 
inadequacy of using experts alone for judging medical evidence is 
unknown, and probably it varies from case to case. Given these 
limitations, however, it is currently generally accepted that expert 
opinion in the absence of data comprises the lowest level of 
evidence in the hierarchy of medical evidence.8 
                                                          
7 The potential conflicts of experts have recently drawn considerable 
attention. See, e.g., J. Abraham, The Science and Politics of Medicines Control, 
26 DRUG SAFETY 135 (2003); Sheldon Krimsky et. al., Scientific Journals and 
Their Authors’ Financial Interests: a Pilot Study, 67 PSYCHOTHERAPY & 
PSYCHOSOMATICS 194 (1998); George N. Papanikolaou et. al., Reporting of 
Conflicts of Interest in Guidelines of Preventive and Therapeutic Interventions, 
1 B.M.C. MED. RES. METHODOLOGY 3 (2001). 
8 There are several different scales for rating evidence. Simple three-tier 
systems such as those used by the United States Preventive Services Task Force 
are commonly adopted or modified. According to this scheme, level I evidence 
corresponds to evidence obtained from at least one properly randomized 
controlled trial; level II corresponds to evidence obtained from well-designed 
controlled trials without randomization (II-1), well-designed cohort or case-
control analytic studies, preferably from more than one center or research group 
(II-2), or multiple time series with or without the intervention or uncontrolled 
experiments with dramatic results (II-3); and level III corresponds to opinions of 
respected authorities, based on clinical experience; descriptive studies and case 
reports; or reports of expert committees. For a comprehensive review of 
available systems to rate the medical evidence, see Suzanne West et. al., Systems 
to Rate the Strength of Scientific Evidence, Agency for Healthcare Research and 
Quality, Evidence report/Technology Assessment Number 47, Apr. 2002. 
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B.  Non-randomized Studies 
There is wide consensus that the strength of the evidence in 
medicine should depend on the amount, quality, and consistency of 
the available data that has been generated from biomedical 
research. The amount of data is important but far from sufficient. 
The quality of the data is very important, since small studies that 
are well designed may give more accurate conclusions than large 
studies that have clear flaws in their design and execution. Finally, 
for each medical question of interest many different studies may 
have been conducted. It is thus important to be able to acquire a 
synthesis of the available evidence and to examine the whole 
picture emerging from the totality of the data. When all the 
different studies on the same question agree, this consistency is 
reassuring, while disagreements need to be probed and explained, 
if possible. Exceptions to the rule are common in medicine. 
1.  Observational and Cross-Sectional Studies 
The quality of medical studies is not straightforward to assess. 
Based on theoretical considerations, however, some types of 
studies are less susceptible to potential errors and biases compared 
with others. Case-reports of single observations and series of cases 
can provide useful information, but they lack a control comparison 
and thus one can only see what has happened to one or several 
patients without being able to tell what might have happened if a 
different course of action had been employed. Therefore, such 
observational studies without a control population are typically 
considered to be superior to plain expert opinion in the absence of 
data, but inferior to other types of study designs.9 The same largely 
holds true of cross-sectional designs, where a population is studied 
in terms of outcomes and candidate factors of interest and 
                                                          
9 There is an effort to improve the quality of case reports in the medical 
literature and to upgrade their status based on the principles of evidence-based 
medicine. See, e.g., MILOS JENICEK, CLINICAL CASE REPORTING IN EVIDENCE-
BASED MEDICINE, (2d ed. 2001); Jan P. Vandenbroucke, In Defense of Case 
Reports and Case Series, 134 ANNALS INTERNAL MED. 330 (2001). 
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associations are evaluated. In such studies, outcomes and candidate 
factors associated with them are measured at the same time, so it is 
not possible to tell where there is a causative relationship in the 
absence of a temporal sequence. 
2.  Case-Control and Retrospective Cohort Studies 
Case-control studies and retrospective cohort studies have the 
advantage that both patients with an adverse outcome and those 
without an outcome of interest are available and that these groups 
can be compared in terms of various factors that may or may not 
be associated with the outcomes. A temporal sequence of events is 
available. Again, however, the detection of significant associations 
on the basis of statistical tests does not guarantee clinical or 
biological causality. Furthermore, there can be bias in the choice of 
the control groups (subjects without the outcome of interest). 
Finally, these studies are retrospective, in that they are based on 
collecting information from the past, and such information may be 
subject to major errors or problems from missing data since the 
data has not been collected with a specific prospective plan in 
mind. 
3.  Prospective Cohort Studies 
Prospective cohort studies have a higher level in the hierarchy 
of evidence. In this case, groups of people are followed into the 
future and the potential association between various factors and 
outcomes can be discerned over time. These studies by definition 
may take a long time to conduct, and they are more expensive than 
retrospective studies, but there is room for better data collection 
according to pre-specified rules. Still, these studies suffer from the 
limitation that people are not assigned randomly to having or not 
having a specific factor, so there is considerable room for bias. For 
example, one can compare patients who had a new aggressive type 
of surgery against those who chose to have the old type of 
operation. It is possible that patients and physicians who choose 
the new aggressive type of intervention are those who have the 
worst or more advanced disease and are desperate to try something 
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new. If they fare worse than those who got the old type of 
operation, this may be due simply to the fact they were at a worse 
condition even before the operation. Conversely, the new operation 
may be reserved only for patients who are in the best possible 
condition if patients and physicians feel the risk of adverse events 
may be too high for patients having any background problems. In 
this case, the new operation may have superb outcomes only 
because the most favorable patients were selected upfront. This 
problem is known as confounding by indication. Confounding may 
involve also a number of other known or unknown patient 
characteristics beyond the severity of illness. Thus, for all semi-
experimental studies (both prospective and retrospective cohort 
studies and case-control studies), to arrive at a net effect of the 
factor of interest, it is important to adjust the compared groups for 
all possible imbalances that may exist between them. Adjustment 
is rarely straightforward, however, and it is unlikely that all 
potential imbalances between the compared groups can be 
identified a priori and taken into account.10 
4.  Randomized Trials 
The problem of confounding is avoided when randomized trials 
are conducted. In randomized trials, subjects are divided into two 
or more groups in a random fashion that guarantees that 
imbalances between the compared groups are unlikely, and if 
present, they are purely due to chance and likely to cancel 
themselves out if a sufficiently large number of subjects can be 
randomized. Randomized trials have been used for over fifty years 
in medicine, and they are accepted as the reference standard for 
assessing the efficacy of medical interventions with the least bias.11 
Even within randomized trials, not all studies are the same. 
Besides sample size, studies may differ on various aspects of study 
                                                          
10 For more details on semi-experimental studies, see KENNETH J. 
ROTHMAN & SANDER GREENLAND, MODERN EPIDEMIOLOGY (1998). 
11 Randomized trials are the perceived gold standard for evidence despite 
their acknowledged limitations. See, e.g., Alejandro R. Jadad & Drummond 
Rennie, The Randomized Controlled Trial Gets a Middle-Aged Checkup, 279 J. 
AM. MED. ASS’N 319 (1998). 
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design. These aspects include whether blinding is used or not; how 
well randomization has been performed; whether the allocation 
sequence has been adequately concealed or not; and whether 
follow up and patient flow has been carefully examined, as far as 
patients withdrawing from the assigned treatment are concerned. 
There is considerable debate on whether these or other study 
parameters may be affecting the results of the trials. Some 
evidence suggests that poor quality studies may tend to inflate the 
estimated efficacy of medical interventions.12 However, quality is 
often hard to define and/or may be difficult to discern from 
published medical reports because what is reported may not be an 
accurate reflection of what actually happened during the trial.13 
Thus in some cases, studies with poor quality characteristics may 
actually show a smaller effect for an experimental intervention 
than studies with good quality ratings.14 In the presence of quality 
defects, the direction of bias in the results is often difficult to 
determine. 
Given this uncertainty, there is increasing understanding that 
the quality of medical research needs to be improved and held at 
high standards. For some medical fields, the overall feeling is that 
the quality of research methods used has been lagging behind 
acceptable standards. Several years ago, the editor of the Lancet 
wrote an editorial where in the title he questioned whether surgical 
trial research exists or is all just “comic opera.”15 Although this 
                                                          
12 See, e.g., Kenneth F. Schulz et. al., Empirical Evidence of Bias. 
Dimensions of Methodological Quality Associated with Estimates of Treatment 
Effects in Controlled Trials, 273 J. AM. MED. ASS’N 408 (1995) (finding that 
lack of allocation concealment inflates the observed treatment effect by 40% and 
lack of double-blinding inflates the treatment effect by about 20%). See also 
Peter Juni et. al., Systematic Reviews in Health Care: Assessing the Quality of 
Controlled Clinical Trials, 323 BRIT. MED. J. 42-46 (2001) (reviewing such 
studies). 
13 John P.A. Ioannidis & Joseph Lau, Can Quality of Clinical Trials and 
Meta-analyses be Quantified?, 352 LANCET 590 (1998). 
14 This has been demonstrated in studies of infectious disease-related 
interventions by Ethan M. Balk et. al., Correlation of Quality Measures with 
Estimates of Treatment Effect in Meta-analyses of Randomized Controlled 
Trials, 287 J. AM. MED. ASS’N 2973 (2002). 
15 Richard Horton, Surgical Research or Comic Opera: Questions, but Few 
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may be an exaggeration, it reflects the difficulties in improving the 
quality of medical research. One vein of effort has focused 
attention on standardizing the reporting of the results of medical 
studies in the peer-reviewed literature. Comprehensive checklists 
that ensure all the important information is conveyed have been 
developed and accepted for randomized trials.16 Efforts are 
underway to develop and agree on similar standards for the 
reporting of other types of studies. 
III.  DIVERSITY OF MEDICAL EVIDENCE 
The hierarchy of evidence discussed above is not cut in stone. 
For some types of important medical questions, some or all of 
these types of study designs may not be equally applicable. For 
example, in studying the effects of potentially harmful factors 
(e.g., the harmful effects of radiation or smoking), it is unethical to 
use randomized trials. Randomized trials may also be infeasible 
when it is difficult to commit individuals to specific interventions, 
e.g., making some behavioral or nutritional changes.17 To evaluate 
the accuracy of diagnostic tests, a different type of study is 
necessary, where people with and without the disease are subjected 
to the diagnostic test of interest and a comparator reference 
standard test to see whether the test under study comes close to the 
reference standard.18 Medical prognosis also cannot be addressed 
with randomized studies, but usually semi-experimental studies are 
                                                          
Answers, 347 LANCET 984 (1996). 
16 The most widely adopted is the Consolidated Standards of Reporting 
Trials (CONSORT). See Doug G. Altman et. al., The Revised CONSORT 
Statement for Reporting Randomized Trials: Explanation and Elaboration, 134 
ANNALS INTERNAL MED. 663 (2001). 
17 This rationale is exemplified by positions held by Meir Stampfer. See 
Meir Stampfer, Observational Epidemiology Is the Preferred Means of 
Evaluating Effects of Behavioral and Lifestyle Modification, 18 CONTROLLED 
CLINICAL TRIALS 494 (1997). 
18 Discussion of diagnostic test studies is beyond the focus of this article. 
For more details, see XIAO-HUA ZHOU, NANCY A. OBUCHOWSKI & DONNA K. 
MCCLISH, STATISTICAL METHODS IN DIAGNOSTIC MEDICINE (2002). 
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used.19 Moreover, even when several different designs can be 
equally applied to a specific question, there is no guarantee that 
studies using designs at a higher level in the hierarchy of evidence 
are necessarily superior to studies using designs at a theoretically 
lower level. Randomized trials sometimes disagree with the results 
of semi-experimental and observational studies on the same 
question,20 but this does not mean that in all such cases of 
disagreements the randomized trials are correct and the 
observational evidence is wrong. Since bias may interfere in all 
kinds of medical studies, sometimes poorly-done randomized 
studies may be more unreliable than well-done cohort studies. 
Furthermore, random error may affect the results of any human 
study; by chance the results of randomized trials may occasionally 
be further away from the truth than the results of other studies. 
Within the same study design, sample size is important to 
consider, and larger studies are likely to be more definitive than 
smaller ones. There is no certainty that they are always likely to be 
more correct, though. Empirical evaluations have shown that small 
studies disagree with larger studies about a quarter of the times 
beyond what would be anticipated by chance alone. In these cases, 
it is not straightforward to tell which one is right or whether both 
small and larger studies provide different sides of the truth and 
complementary evidence. Interestingly, it has also been found that 
large trials (defined as studies with at least 1,000 patients) disagree 
among themselves about as frequently as the discrepancy between 
                                                          
19 However, it is possible to evaluate whether the application of a 
prognostic system improves patient outcomes in the long-term or the efficiency 
and cost-benefit of the health system. The same holds true for the application of 
diagnostic tests. Such applications and their effects may then be studied with 
randomized trials. 
20 See, e.g., John P.A. Ioannidis et. al., Comparison of Evidence of 
Treatment Effects in Randomized and Nonrandomized Studies, 286 J. AM. MED. 
ASS’N 821 (2001) (comparing large versus smaller trials); but see, e.g., John 
Concato et. al., Randomized, Controlled Trials, Observational Studies and 
Randomized, Controlled Trials, 342 NEW. ENG. J. MED. 1878 (2000) (offering a 
dissenting view). For discrepancies between very large trials (also called 
“megatrials”), see T.A. Furukawa et. al., Discrepancies among Megatrials, 53 J. 
CLINICAL EPIDEMIOLOGY 1193 (2000). 
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large trials and meta-analyses of small trials.21 
In all, it is unavoidable that sometimes studies seemingly 
addressing the same question may reach different results. There 
could be many reasons for this variability. Studies are conducted 
with different designs, at different settings, in different 
populations, with different background management and treatment, 
in different countries, at different time periods.22 All of these 
factors, in addition to the play of chance, could contribute to 
variability. The whole emerging picture may be quite confusing 
when an effort is made to reach a final conclusion even by the 
most well informed and experienced experts. The quantity of data, 
although useful in assessing consistency, can be overwhelming. 
Systematic reviews and meta-analyses can provide a transparent 
framework in such situations to make sense of the disparate data. 
IV.  SYSTEMATIC REVIEWS AND META-ANALYSES 
A systematic review is a comprehensive assessment of the 
medical literature on a topic of interest using a priori specified 
rules for the search, identification, and eligibility of the pertinent 
studies and for the abstraction of relevant data.23 The systematic 
nature of the process according to clear-cut rules differentiates a 
                                                          
21 Several empirical evaluations have been published on the rate and 
reasons of disagreements between small and larger studies. See John P.A. 
Ioannidis et. al., Issues in Comparisons between Meta-analyses and Large 
Trials, 279 J. AM. MED. ASS’N 1089 (1998); Joseph C. Cappelleri et. al., Large 
Trials vs Meta-analysis of Smaller Trials: How Do Their Results Compare?, 276 
J. AM. MED. ASS’N 1332 (1996); Jose Villar et. al., Predictive Ability of Meta-
analyses of Randomized Controlled Trials, 345 LANCET 772 (1995); Jacques 
LeLorier et. al., Discrepancies between Meta-analyses and Subsequent Large 
Randomized, Controlled Trials, 337 N. ENG. J. MED. 536 (1997); T. A. 
Furukawa et al., Discrepancies among Megatrials, 53 J. CLIN. EPIDEMIOLOGY 
1193 (2000). 
22 Joseph Lau et. al., Summing up Evidence: One Answer Is Not Always 
Enough, 351 LANCET 123 (1998). 
23 Deborah J. Cook et. al., Systematic Reviews: Synthesis of Best Evidence 
for Clinical Decisions, 126 ANNALS INTERNAL MED. 376 (1997); Cynthia D. 
Mulrow et. al., Systematic Reviews: Critical Links in the Great Chain of 
Evidence, 126 ANNALS INTERNAL MED. 389 (1997). 
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systematic review from a traditional review authored by experts 
without specific rules. Systematic reviews currently have assumed 
a key place in the generation of recommendations for medical 
practice and for clinical decision-making.24 An international 
initiative such as the Cochrane Collaboration is aiming to conduct 
systematic reviews to cover all major aspects of health care.25 As 
of the fall of 2003, the Cochrane Library includes 1,754 completed 
Cochrane reviews and 1,304 protocols for ongoing reviews. In 
addition, there are 4,123 abstracts of completed systematic reviews 
in medical journals, theses, and reports that have been included in 
the Database of Abstracts of Reports of Effects (DARE), also a 
part of the Cochrane Library.26 In the United States, the Agency 
for Healthcare Research and Quality has designated 13 evidence-
based practice centers to produce comprehensive evidence reports 
and technology assessments on a variety of health care topics.27 
Over 100 of these reports have been produced over the past six 
years. These reports are based on systematic reviews of the 
medical literature and analyses of relevant databases, and are used 
by various government agencies and professional and health care 
organizations. 
Systematic reviews target upfront a precisely defined clinical 
question or set of questions. Depending on the question and the 
                                                          
24 Lisa A. Bero & Alejandro R. Jadad, How Consumers and Policymakers 
Can Use Systematic Reviews for Decision Making, 127 ANNALS INTERNAL MED. 
37 (1997); Deborah J. Cook et. al., The Relation between Systematic Reviews 
and Practice Guidelines, 127 ANNALS INTERNAL MED. 210 (1997). 
25 See THE COCHRANE COLLABORATION, at http://www.cochrane.org (last 
visited March 2, 2004); Lisa Bero & Drummond Reenie, The Cochrane 
Collaboration: Preparing, Maintaining, and Disseminating Systematic Reviews 
of the Effects of Health Care, 274 J. AM. MED. ASS’N 1935 (1995); Mike Clarke 
& Peter Langhorne, Revisiting the Cochrane Collaboration: Meeting the 
Challenge of Archie Cochrane—and Facing up to Some New Ones, 323 BRIT. 
MED. J. 821 (2000). 
26 See THE COCHRANE COLLABORATION, at http://www.cochrane.org (last 
visited March 2, 2004) (access to the Cochrane Library is limited to those with a 
subscription). 
27 See AGENCY FOR HEALTHCARE RESEARCH & QUALITY, AHRQ PUB. NO. 
03-P006, EVIDENCE-BASED PRACTICE CENTERS (2003), at http://www.ahrq. 
gov/clinic/epc/. 
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eligibility criteria that are considered appropriate for selecting 
studies on the question(s), some systematic reviews may include a 
large number of eligible studies, while others may systematically 
scrutinize hundreds and thousands of references from the medical 
literature, only to conclude that no eligible study exists that 
directly addresses the question of interest.28 Systematic reviews 
that identify such lack of evidence are still useful since they clearly 
show the direction for designing new studies in a field where 
evidence-based inferences are urgently needed. Even in the 
presence of data, systematic reviews may often conclude that the 
available evidence is insufficient, controversial, or inconclusive 
and that further studies are needed. In other cases, systematic 
reviews conclude that the available data from several studies is 
consistent and conclusive. 
Even in the presence of systematic methods for locating and 
appraising evidence, a systematic review can hardly be conclusive 
unless the collected data can be appropriately synthesized in a 
quantitative fashion. A meta-analysis is a quantitative synthesis of 
data from various sources addressing the same question; a 
systematic review is a prerequisite to a good meta-analysis. Most 
meta-analyses use statistical methods to combine data from 
published studies, and the information is available at the level of 
groups, e.g., the outcomes in patients in each compared group. 
Such meta-analyses of group data or meta-analyses of the 
published literature are basically retrospective designs and have 
several limitations including using only data that are available. 
Meta-analyses may also be designed prospectively to collect 
necessary data as well as to improve the consistency of collected 
data, i.e., with a plan to combine the results from several studies 
that are to be conducted.29 Furthermore, meta-analyses may be 
                                                          
28 For example, a systematic search of studies that might yield information 
on how to tell whether a very common condition, acute conjunctivitis, is due to 
viruses or bacteria, found no good study that had assessed the utility of clinical 
signs and symptoms for making this diagnosis. See Remco P. Rietveld et. al., 
Diagnostic Impact of Signs and Symptoms in Acute Infectious Conjunctivitis: 
Systematic Literature Search, 327 BRIT. MED. J. 789 (2003). 
29 For prospective meta-analysis may start with the construct of a study 
registry that tries to capture all studies performed on a specific topic right from 
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extended to use not only group data, but data from individual 
patients. Such individual-level data meta-analyses collate 
information from diverse pertinent studies with data on each 
patient on the exposures and outcomes of interest as well as a set 
of other parameters that may be considered to be of interest.30 
Clearly, meta-analyses of individual-level data are more difficult to 
conduct, and their performance must be justified by considering 
whether they are likely to provide additional or far more exact 
results compared to meta-analyses of group data. 
A.  Place of Systematic Reviews and Meta-analyses in Medical 
Decision-Making 
Most schemes of the hierarchy of evidence have accepted that 
meta-analyses, especially those of randomized trials, are the 
highest level of medical evidence.31 This is due to the fact that 
meta-analyses may combine data from a large number of studies 
and, given their systematic background, they have an objective 
opportunity for quantifying effects and associations, finding out 
whether the data are consistent, and in some cases, also quantifying 
the extent of inconsistency and probing into potential reasons for 
the existence of discrepancies between studies. 
By definition, systematic reviews and meta-analyses are highly 
focused research designs. They address a specific question or a few 
questions, and it is unlikely that they can cover all the tangible and 
intangible issues that are involved in decision making. There is 
increasing appreciation that systematic reviews and meta-analyses 
should try to cover aspects of both efficacy and safety when 
medical interventions are involved. This is often very difficult to 
do because the quality and quantity of available data to assess the 
                                                          
their beginning (at the time they are designed or launched). 
30 For meta-analysis of individual-level data, see Leslie A. Stewart & M.K. 
Parmar, Meta-analysis of the Literature or of Individual Patient Data: Is There 
a Difference?, 341 LANCET 418 (1993); Leslie A. Stewart & Mike J. Clarke, 
Practical Methodology of Meta-analyses (Overviews) Using Updated Individual 
Patient-Data—Cochrane Working Group, 14 STATISTICS IN MED. 2067 (1995). 
31 See, e.g., Robin Harbour & Juliet Miller, A New System for Grading 
Recommendations in Evidence Based Guidelines, 323 BRIT. MED. J. 334 (2001). 
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benefits and harms of medical interventions varies a great deal.32 
Even if several aspects of a clinical problem can be covered by a 
meta-analysis, it is unlikely that a final decision can be made 
directly on the basis of such evidence. Decision-making may 
involve other important parameters such as cost issues; the 
availability of resources; the availability or lack thereof of 
alternative interventions; utility ranking when several, diverse 
outcomes are involved; priority setting and overall strategic design 
in institutions or health care systems; and the subjective 
preferences of the patient. 
Thus systematic reviews and meta-analyses provide some 
highly filtered and carefully analyzed information that needs to be 
placed in a broader context. Although physicians are increasingly 
educated in understanding these research tools, often the subtleties 
of meta-analyses may go beyond the appreciation of many 
practitioners and health care workers. However, the results and 
inferences of meta-analyses may be used efficiently for generating 
more easily interpretable clinical directives. Clinical practice 
guidelines, for example, are documents that aim to distill 
recommendations for important medical practice decision-making. 
In the past, most guidelines suffered from the same problems as 
expert reviews, since they were generated typically by one or 
several experts without any particular attention to the scientific 
basis of collecting, appraising, and synthesizing the available 
evidence. Major deficiencies in the quality of guidelines, even 
those published by top quality medical journals and reputable 
specialist societies have recently been scrutinized.33 A robust 
                                                          
32 Luis Gabriel Cuervo & Mike Clarke, Balancing Benefits and Harms in 
Health Care: We Need to Get Better Evidence about Harms, 327 BRIT. MED. J. 
65 (2003). 
33 Defects on guidelines have been identified on their development, 
reporting, evidence base, and transparency. See, e.g., Roberto Grilli et. al., 
Practice Guidelines Developed by Specialty Societies: The Need for a Critical 
Appraisal, 355 LANCET 103 (2000); T.M. Shaneyfelt et. al., Are Guidelines 
Following Guidelines? The Methodological Quality of Clinical Practice 
Guidelines in the Peer-Reviewed Medical Literature, 281 J. AM. MED. ASS’N 
1900 (1999); Ioannis A. Giannakakis et. al., Citation of Randomized Evidence in 
Support of Guidelines of Therapeutic and Preventive Interventions, 55 J. 
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process must be set for producing high-quality guidelines. This 
process includes the systematic appraisal of the available data and 
a transparent procedure for reaching consensus among experts 
involved in guideline development, clarity in the presentation of 
alternative options, a balance of risks and benefits, editorial 
independence, and rigorous standards for prompt updating to 
include newly released research data that, in some cases, may 
strengthen, modify, or invalidate prior beliefs.34 
B.  Cumulative Meta-analysis 
In this regard, meta-analysis can be seen as an exercise of 
updating the totality of available information over time. In 
cumulative meta-analysis, studies on a given medical question are 
ordered chronologically.35 The results of each study are added one 
at a time in the order in which they appear. Cumulative meta-
analysis provides a picture of evolving trends as medical evidence 
accumulates. It is possible to examine whether evidence has 
remained steady over time or major fluctuations have occurred 
over time. For example, occasionally, initial studies suggested an 
intervention may be highly effective, while subsequent studies may 
show that the same intervention is totally ineffective. Such big 
changes are infrequent when a large amount of evidence has 
accumulated from large and/or several studies. In some cases, 
however, changes were seen even when many early studies, 
including large ones, had accumulated over time. 
For example, several studies on the efficacy of intravenous 
magnesium salts in acute myocardial infarction, including a study 
                                                          
CLINICAL EPIDEMIOLOGY 545 (2002). 
34 A widely adopted checklist for appraising guidelines has been developed 
by the AGREE Collaboration. See AGREE Collaboration, Development and 
Validation of an International Appraisal Instrument for Assessing the Quality of 
Clinical Practice Guidelines: the AGREE Project, 12 QUALITY & SAFETY 
HEALTH CARE 18 (2003). 
35 Joseph Lau et. al., Cumulative Meta-analysis of Therapeutic Trials for 
Myocardial Infarction, 327 N. ENG. J. MED. 248 (1992); Joseph Lau et. al., 
Cumulative Meta-analysis of Clinical Trials Builds Evidence for Exemplary 
Medical Care, 48 J. CLINICAL EPIDEMIOLOGY 45 (1995). 
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of 2,300 patients, had clearly documented large, significant 
reductions in the mortality risk with this inexpensive intervention. 
A larger study of over 50,000 patients showed no effect at all, 
however, and the same lack of efficacy was documented in a 
subsequent study with over 6,000 patients.36 Thus, 
recommendations on the use of this therapy would change 
dramatically over time, based on the evolution of meta-analysis 
results. The interpretation of this example is further complicated by 
the fact that the standard of care of patients in these trials has 
evolved considerably over time. Many of the patients in the later 
trials were concurrently receiving other forms of effective 
treatments, thus confounding the interpretation of the results. 
Comparison of the older trials and the newer ones may no longer 
be valid and the treatment being evaluated may no longer be 
relevant, given the current standard of care. 
In another example, several very large non-randomized studies 
of over 10,000 subjects suggested that estrogen replacement is a 
highly beneficial intervention for post-menopausal women with 
strong protective effects against cardiovascular disease. 
Nevertheless, a large randomized study showed clearly that there is 
no cardiovascular protection and the overall balance of risks 
against benefits makes estrogen replacement a highly unfavorable 
course of action for women in this age group.37 In the case of 
estrogen replacement, different study designs (observational vs. 
randomized data) led to different conclusions, even though both 
types of designs entailed very large numbers of subjects. 
                                                          
36 For more details on the magnesium controversy, see the report of the 
latest relevant trial: Magnesium in Coronaries (MAGIC) Trial Investigators, 
Early Administration of Intravenous Magnesium to High-Risk Patients with 
Acute Myocardial Infarction in the Magnesium in Coronaries (MAGIC) Trial: A 
Randomised Controlled Trial, 360 LANCET 1189 (2002). That report also alludes 
to the prior evidence on this controversial topic. 
37 The Women’s Health Initiative (WHI) trial was the pivotal study that 
reversed prior beliefs on the indications of estrogen replacement in post-
menopausal women. The study results have been published in a series of 
manuscripts in the Journal of the American Medical Association in 2002 and 
2003 and have been extensively commented on in the scientific and lay 
literature. 
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The cases where large changes have occurred in our 
appreciation of the role of specific medical interventions are 
probably the exception, rather than the rule. In most cases, medical 
evidence does not change so much over time. Provided that they 
are well conducted,38 systematic reviews and meta-analyses may 
thus provide the scientific ground for trusting the adequacy of 
medical actions or lack thereof in specific settings. Still, the 
evolutionary, cumulative nature of medical evidence should be 
kept in mind as a way of understanding that uncertainty about 
medical actions is unlikely to disappear completely even with 
large-scale evidence and well-conducted studies. 
C.  Methods of a Systematic Review 
The general approach to conducting a systematic review 
consists of the following steps: 
• Formulate answerable research question(s) 
• Define the systematic review (meta-analysis) protocol 
(establish inclusion and exclusion criteria) 
• Perform literature search 
• Screen titles and abstracts of literature search results for 
potentially relevant studies and retrieve full articles 
• Evaluate full articles according to criteria 
• Critically appraise articles that met criteria 
• Extract data for analysis 
• Perform meta-analyses and sensitivity analyses as 
appropriate 
• Interpret results 
One of the most important tasks in conducting a systematic 
                                                          
38 The conduct of meta-analysis requires rigorous standards as that of any 
good research. Guidelines have been developed for the reporting of meta-
analyses. See, e.g., David Moher et. al., Improving the Quality of Reports of 
Meta-analyses of Randomised Controlled Trials: The QUORUM Statement. 
Quality of Reporting Meta-analyses, 354 LANCET 1896 (1999); Donna F. Stroup 
et. al., Meta-analysis of Observational Studies in Epidemiology: A Proposal for 
Reporting. Meta-analysis of Observational Studies in Epidemiology (MOOSE) 
Group, 283 J. AM. MED. ASS’N 2008 (2000). 
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review is defining the question of interest and its limits.39 This is 
important, since reviews with similar target-questions may reach 
different conclusions if they have important differences on how 
exactly the questions of interest are defined. It is important to 
clarify the interventions or associations of interest; what types of 
studies are to be examined and why some specific types of studies 
are to be selected or excluded; what types of people are eligible for 
including in these studies; which clinical settings are eligible and 
which ones are not; and also what electronic or other databases of 
medical information are to be searched for identifying the relevant 
studies. 
Some subtle decisions may make a difference sometimes. For 
example, should published studies only be included or should 
abstracts be eligible as well?40 For a recently targeted topic of 
interest, much of the pertinent literature may still be in abstract 
form, but for long-standing medical questions this is rarely an 
issue. Another problem is whether both English and foreign-
language sources of evidence should be used. A tower of Babel 
bias has been described according to which non-English speaking 
scientists may publish their results in English language journals 
when they find significant differences, while they may prefer 
native language journals when their results show no significant 
differences.41 Hopefully, the English language covers the 
overwhelming majority of the current scientific literature, so in 
most instances this problem is not a major issue, but exceptions 
may occur. Moreover, a reverse tower of Babel bias has been 
described; where all the Chinese and Russian language articles on 
acupuncture published in local non-English journal have 
significant results.42 
                                                          
39 Carl Counsell, Formulating Questions and Locating Primary Studies for 
Inclusion in Systematic Reviews, 127 ANNALS INTERNAL MED. 380 (1997). 
40 Maureen O. Meade & W.S. Richardson, Selecting and Appraising 
Studies for a Systematic Review, 127 ANNALS INTERNAL MED. 531 (1997). 
41 Matthias Egger et. al., Language Bias in Randomised Controlled Trials 
Published in English and German, 350 LANCET 326 (1997). 
42 Andrew Vickers et. al., Do Certain Countries Produce Only Positive 
Results? A Systematic Review of Controlled Trials, 19 CONTROLLED CLINICAL 
TRIALS 159 (1998). 
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Other parameters that relate to the way the clinical question is 
circumscribed may have an even greater impact on the conclusions 
of a systematic review. Sometimes, a systematic review may have 
very loose eligibility criteria and may include people who differ in 
important aspects among themselves. In this case, one may 
question whether the overall findings of the review may be 
extrapolated equally to each type of people and settings. In other 
situations, a systematic review may use very narrow eligibility 
criteria. This would result in a more sharpened target-population 
where the results would be pertinent, but at the cost of the potential 
to generalize and with considerable loss of potentially useful 
information.43 
D.  Methods of a Meta-analysis 
These considerations affect also the interpretation of a meta-
analysis, since the first step towards conducting a quantitative 
synthesis of the data is typically the conduct of a systematic 
review. However, in a meta-analysis there are additional 
methodological issues that need to be decided and that may affect 
the results and their interpretation. We will avoid mathematical 
details in our presentation of the key issues, focusing on the 
meaning of the key issues and the impact that they may have. 
First, there exist a large number of statistical methods for 
combining data across studies.44 Even though these methods may 
seem to an outsider to be a source of potentially large diversity, 
empirical evidence suggests this is not a major concern.45 
                                                          
43 For example, a large number of meta-analyses (at least 9 we are aware 
of) have been conducted trying to evaluate whether it is better to administer 
these drugs once a day or multiple times a day in terms of the potential to 
damage the kidneys and their efficacy for treating infections. The number of 
studies included in these meta-analyses has varied by more than 3-fold since the 
eligibility criteria of the different teams conducting the meta-analyses were 
different. 
44 For a brief, non-technical overview, see Joseph Lau et. al., Quantitative 
Synthesis in Systematic Reviews, 127 ANNALS INTERNAL MED. 820 (1997). 
45 See, e.g., Jose Villar et. al., Meta-analyses in Systematic Reviews of 
Randomized Controlled Trials in Perinatal Medicine: Comparison of Fixed and 
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Moreover, as the field of meta-analysis has matured over time, 
analytical approaches have become more standardized. The first 
step usually is to evaluate whether there is any formal, statistically 
significant heterogeneity (diversity) between the results of the 
eligible studies included in the meta-analysis. The detection of 
formal heterogeneity does not mean that something is wrong with 
the data used in the meta-analysis, but it provides a hint that the 
results of the constituent studies differ between themselves. 
Between-study differences may exist either because of genuine 
diversity or because of bias, or in some cases chance may have 
played its role. Conversely, when the heterogeneity test is not 
significant, one cannot rule out completely that genuine diversity 
and/or bias may exist, especially when the number of studies is 
limited and the test has limited power to identify existing 
diversity.46 
One commonly used approach in many meta-analyses is the 
estimation of an overall effect (average). The average is not 
obtained by simply summing up the data, since this may lead to 
paradoxical results and erroneous conclusions. Instead, the results 
of each study are given a weight inversely proportional to the 
uncertainty (variance) of the results, which is a function of the total 
number of study subjects and the number of events. Large studies 
with little uncertainty in their estimates are thus given more weight 
than smaller studies. In the presence of major differences in the 
results of the various studies, even this weighting approach may be 
inappropriate, since it assumes that all studies have different results 
due to chance alone, something that seems unlikely in this setting. 
Appropriate statistical models are available that also take into 
account the extent of diversity in the study results in generating a 
summary estimate. 
In the presence of significant differences between studies, there 
                                                          
Random Effects Models, 20 STAT. MED. 3635 (2001). 
46 Empirical evidence and technical considerations on heterogeneity are 
covered by Julian Higgins et. al., Statistical Heterogeneity in Systematic 
Reviews of Clinical Trials: A Cricial Appraisal of Guidelines and Practice, 7 J. 
HEALTH SERVICES RES. & POL’Y 51 (2002); Eric Engels et. al., Heterogeneity 
and Statistical Significant in Meta-analysis: An Empirical Study of 125 Meta-
analyses, 19 STATISTICS IN MED. 1707 (2000). 
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are several other methods that can be used in trying to explain and 
understand this heterogeneity. Meta-regression methods try to 
relate common characteristics with differences in the results across 
several studies. These methods are helpful when there are a large 
number of studies.47 The analyses are mostly exploratory and 
generate results that usually would have to be validated in 
subsequent research. Moreover, some of these analyses are subject 
to the ecological fallacy (when inferences based on average 
characteristics of a group are extrapolated and applied to 
individuals who comprise the group). 
Another approach is multivariate modeling, and this is feasible 
in meta-analyses of individual-level data. In this case, for each 
patient in each study, information is available on several different 
characteristics. One can then test whether the results are affected or 
modified in the presence of each of these characteristics or 
combinations thereof. These analyses are also exploratory, but they 
may help clarify why diversity exists in the results of various 
studies. At the end of the analysis, it may be possible to identify 
subgroups of people who are different in their responses to the 
same medical intervention or who have different magnitudes of 
benefit and/or risk in relationship to the same intervention.48 
It has been debated whether it is better to have one single large 
study rather than a meta-analysis of several smaller studies. Large 
studies are useful, but for most medical questions of interest they 
are never performed. Therefore, the constellation of several small 
clinical studies may be all that is available. Even if large studies 
have been done, it is not certain that their results would be more 
reliable than the results of smaller studies. Most often, all studies, 
big and small, offer complementary evidence on a question of 
interest. 
                                                          
47 For more details on meta-regressions and their relationship to other 
commonly used meta-analysis methods, see Sander Greenland, Invited 
Commentary: A Critical Look at Some Popular Meta-analytic Methods, 140 
AM. J. EPIDEMIOLOGY 290 (1994). 
48 Thomas A. Trikalinos & John P.A. Ioannidis, Predictive Modeling and 
Heterogeneity of Baseline Risk in Meta-analysis of Individual Patient Data, 54 
J. CLINICAL EPIDEMIOLOGY 245 (2001). 
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E. Other Considerations in Meta-analysis 
1. The Relationship between Quality and Selection 
As discussed earlier, the results of systematic reviews and 
meta-analyses may be affected by how comprehensive the criteria 
are for selecting the studies to be included. Sometimes criteria may 
be set on the basis of the perceived quality of studies; studies 
considered to be of poor quality may be excluded or studies of 
perceived poor quality may be contrasted against those of high 
quality. The quality and potential deficits thereof should be 
assessed in each of the studies considered for inclusion in a meta-
analysis. However, quality may often be difficult to quantify, and 
the effect of poor quality on the results of a study may often be 
unpredictable. Some investigators have suggested that more weight 
should be given to the results of high-quality studies.49 This is a 
problematic approach since the allocation of differential weight 
does not correct the quality deficits and it is unknown whether it 
leads the summary results closer to the truth. The detection of 
quality defects is important to give insight about how to improve 
future research in the field and to give a hint about the uncertainty 
that may accompany the research findings, especially when poor 
quality is documented. One may have to give less credibility to (or 
even discount) the results of poorly designed research, even if the 
conclusions seem to be strong and beyond dispute from a purely 
statistical perspective. 
2. Publication Bias 
Another issue to be considered is the possibility of publication 
bias. Publication bias reflects the fact that small studies with 
“negative” results may not be published because investigators, 
peer-reviewers, and/or editors don’t find them as interesting as 
                                                          
49 David Moher et. al., Does Quality of Reports of Randomised Trials Affect 
Estimates of Intervention Efficacy Reported in Meta-analyses?, 352 LANCET 609 
(1998). 
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studies that find statistically significant results (“positive” 
studies).50 The terms “positive” and “negative” are misnomers 
since well designed and conducted studies should be important 
sources of evidence regardless of what their results are. The 
selection of “positive” studies may nevertheless lead to spurious 
impressions when data are synthesized. Another possibility is time 
lag bias,51 according to which studies with negative results may 
eventually be published, but they take longer to do so, as compared 
with those with “positive” results. Time lag bias will also result in 
more favorable estimates of effects when early data are 
synthesized and in diminishing effects as a more complete picture 
emerges over time.52 
Several tests have been developed that try to detect publication 
bias. These tests basically examine whether small studies tend to 
give different results as compared with larger ones; or they try to 
investigate whether the results of a meta-analysis would change 
under the assumption that certain “negative” studies are imputed to 
have been lost and their putative results are added to the overall 
calculations.53 Time lag bias may be examined by performing 
                                                          
50 Publication bias has been documented both for randomized trials and for 
observational studies. See, e.g., Phillipa J. Easterbrook et. al., Publication Bias 
in Clinical Research, 337 LANCET 867 (1991); Kay Dickerin et. al., Factors 
Influencing Publication of Research Results: Follow-up of Applications 
Submitted on Two Institutional Review Boards, 267 J. AM. MED. ASS’N 374 
(1992). 
51 John P.A. Ioannidis, Effect of the Statistical Significance of Results on 
the Time to Completion and Publication of Randomized Efficacy Trials, 279 J. 
AM. MED. ASS’N 281 (1998); Jerome M. Stern & R. John Simes, Publication 
Bias: Evidence of Delayed Publication in a Cohort Study of Clinical Research 
Projects, 315 BRIT. MED. J. 640 (1997). 
52 John P.A. Ioannidis et. al., Recursive Cumulative Meta-analysis: A 
Diagnostic for the Evolution of Total Randomized Evidence from Group and 
Individual Patient Data, 52 J. CLINICAL EPIDEMIOLOGY 281 (1999). 
53 Matthias Egger et. al., Bias in Meta-analysis Detected by a Simple, 
Graphical Test, 315 BRIT. MED. J. 629 (1997); Alex J. Sutton et. al., Empirical 
Assessment of Effect of Publication Bias on Meta-analyses, 320 BRIT. MED. J. 
1574 (2000); Sue Duval & R. Tweedie, Trim and Fill: A Simple Funnel-Plot-
Based Method of Testing and Adjusting for Publication Bias in Meta-analysis, 
56 BIOMETRICS 455 (2000). 
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cumulative meta-analyses. One may notice whether the summary 
results tend to change in the same direction over time, in particular 
when there is an indication of continuously diminishing summary 
effects. These tests have their limitations. Genuine heterogeneity 
may also give the same picture as publication bias,54 but all these 
tests may give signals that a simple grand mean approach may be 
missing important parts of the picture of the evidence. 
CONCLUSIONS AND LEGAL IMPLICATIONS 
Medical evidence is complex; it is heterogeneous and of 
variable quality. Interpreting medical evidence is difficult. 
Evidence must be appraised in its totality using robust systematic 
approaches. Quantitative methods are required to achieve a 
synthesis of the data across an increasing number of studies of the 
same topic. Evidence is cumulative and may change over time, as 
more data accumulate. Moreover, evidence, even when derived 
from well-conducted studies, is subject to biases that may stem 
from factors that are unrelated to the excellent performance of 
isolated single investigations. Meta-analysis offers a useful tool to 
summarize evidence across many studies, identify heterogeneity, 
search for possible explanations for the presence of this diversity, 
and offer hints about the possibility of existing bias. Even the best 
evidence and the best meta-analyses thereof are not sufficient for 
medical decision-making. Most medical decisions are complex and 
require a frame of interpretation. Physicians should try to use the 
best tools to justify their actions in everyday health care. 
Systematic reviews and meta-analyses as well as evidence-based 
recommendations that stem from them are one means for 
enhancing the certainty and confidence of physicians about their 
actions and can be used to justify medical practice. However, they 
also provide a measure of the uncertainty that lies behind these 
                                                          
54 See, e.g., Jonathan A. Sterne et. al., Publication and Related Bias in 
Meta-analysis: Power of Statistical Tests and Prevalence in the Literature, 53 J. 
CLINICAL EPIDEMIOLOGY 1119 (2000). Some of the most commonly used tests 
may sometimes be difficult to interpret. See, e.g., J.L. Tang & J.L. Liu, 
Misleading Funnel Plot for Detection of Bias in Meta-analysis, 53 J. CLINICAL 
EPIDEMIOLOGY 477 (2000). 
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actions. 
From a legal perspective, it is important that judges and 
lawyers become more familiar with the advent of these evidence-
based tools. While judicial decisions may continue to seek expert 
testimonies, such testimonies should be increasingly based on solid 
scientific evidence rather than expert opinion. Typically, a judge or 
a lawyer may find it difficult to probe behind an expert’s opinion 
to evaluate or test the level of credibility based on concepts of best 
available evidence. Experts in court are typically challenged and 
accepted on the basis of their qualifications, conflicts of interest, or 
biases, and not on the value of their opinions. However, it would 
be useful to understand that the medical expert is only one part of 
the long chain of the medical evidence, and that there often can be 
considerable uncertainty behind expert statements. 
 
